Asian Health Care Spending Set For Sharp Rise

13 February 1995

Although health care spending is low in South Asia, averaging just $2.40 per capita in 1990, expenditure is set to increase sharply as populations age and the "tiger economies" reap the benefit of the money that has been released, according to a new report from strategic management consultancy company Datamonitor.

As in the developed countries, but on a larger scale, private health care (direct payment since medical insurance, as yet, is virtually unknown) is used by those who can afford it in preference to the public sector. However, this situation is not likely to last, the report notes, since a properly functioning welfare state is seen as a prerequisite for a modern state, both in South Asia and elsewhere. As incomes rise, developing states will be able to finance new welfare structures via taxes.

In China and Vietnam, where the economy is relatively under-developed, growth is likely to be rapid, while in Hong Kong, Taiwan and South Korea growth is likely to be slower, the report notes. Only in private health care will the more developed economies show the greater growth.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight